Daniel Stewart, MD
Interventional Cardiology · Louisville, KYNPI 1770701237
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $205,368 of the $289,802 with a category attached, or 70.9%. 27 manufacturers reported payments, led by Amgen at 38.8% of the total. Among interventional cardiology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 990 payments — averaging $292.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$113K
- AstraZeneca$97K
- Boston Scientific$51K
- Medtronic$9K
- Teleflex LLC$6K
- Edwards Lifesciences$5K
- plus $9K from 21 others
What the payments were for
- Consulting fees$36,97513%
- Speaking & faculty fees$205,36871%
- Travel & lodging$15,0745%
- Food & beverage$30,45311%
- Education$1,9321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 106 | $112,583 |
| AstraZeneca | 209 | $97,288 |
| Boston Scientific | 329 | $51,163 |
| Medtronic | 51 | $8,707 |
| Teleflex LLC | 28 | $6,489 |
| Edwards Lifesciences | 43 | $4,725 |
| Abbott | 69 | $4,002 |
| Inari Medical, Inc. | 20 | $1,383 |
| Abiomed | 76 | $996 |
| Biotronik Inc. | 12 | $486 |
| Heartflow, Inc. | 3 | $335 |
| Stryker | 7 | $275 |
| Chiesi USA, Inc. | 3 | $253 |
| Ancora Heart, Inc. | 6 | $206 |
| Shockwave Medical, Inc | 2 | $195 |
| Penumbra, Inc. | 1 | $181 |
| Lexicon Pharmaceuticals, Inc. | 1 | $120 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $84 |
| Astellas Pharma US Inc | 1 | $83 |
| Novartis | 4 | $78 |
| Cardiovascular Systems Inc. | 7 | $61 |
| Terumo Medical Corporation | 2 | $26 |
| Atricure, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Cardinal Health 200 LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$111,270
- BRILINTA$75,868
- FARXIGA$18,539
- GENERAL - THERAPIES$8,439
- GENERAL BALLOONS$7,500
- AVVIGO Guidance System$6,615
- SYMPLICITY G3$5,472
- GENERAL VASCULAR ACCESS$4,800
- CATHETERS - ARROW$1,800
- FLOWTRIEVER CATHETER, S$1,380
- CT THROMBECTOMY SYSTEM KIT$1,085
- COREVALVE EVOLUT R$918
- Edwards SAPIEN 3 Transcatheter Heart Valve$700
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$651
- PASCAL$615
- GENERAL GUIDEWIRES$500
- WATCHMAN Access System$366
- SAPIEN 3 Ultra RESILIA$309
- FFRct$269
- TURNPIKE$266
How this compares
$289,802 in reported general payments places this provider in the 95th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $126,232 |
| BrilintaTicagrelor | 112 | $83,091 |
| XareltoRivaroxaban | 44 | $45,609 |
| Repatha SureclickEvolocumab | 39 | $24,202 |
| FarxigaDapagliflozin Propanediol | 16 | $22,226 |
| Repatha SyringeEvolocumab | 13 | $7,123 |
| Ranolazine ErRanolazine | 38 | $3,437 |
| Prasugrel Hcl | 27 | $3,230 |
| ClopidogrelClopidogrel Bisulfate | 295 | $2,468 |
| Nebivolol Hcl | 26 | $1,657 |
| Amiodarone Hcl | 18 | $1,416 |
| Rosuvastatin Calcium | 122 | $1,230 |
| Metoprolol Succinate | 83 | $1,185 |
| Irbesartan | 57 | $1,079 |
| Carvedilol | 137 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $97,288 | $105,317128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Louisville
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ravi SharmaLouisville$86K
- Christopher SemderLouisville$50K
- Sadip PantLouisville$43K
- Michael FlahertyLouisville$42K
- Prafull RahejaLouisville$27K
- Faraaz RahmanLouisville$22K
- Hussayn AlrayesLouisville$21K
- Ivan PenaLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.